ALTCAR.CD30 cells

Phase 1Biologic

UUNC Lineberger Comprehensive Cancer Center

ALTCAR.CD30 cells is one of 15 biologic programs targeting T Cells. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

T CellsActive, not recruiting

T CellsPhase 1

Active, not recruiting

Competition

Competitive Landscape

20 competitors in T Cells

#DrugCompanyPhaseTrials

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Fludara

Sanofi

Phase 2

7 3

Quercetin

MMayo Clinic

Phase 3

1 4

Keytruda

Merck & Co.

Phase 1

2 5

CD19 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 2

2 6

CAR T Cells

CChongqing Precision Biotech Co., Ltd

Phase 2

2 7

Treanda

AAzurity Pharmaceuticals

Phase 1

1 8

Cyclophosphamide,fludarabine

HHebei Senlang Biotechnology Inc., Ltd.

Phase 1

1 9

CDX-1140

CCelldex Therapeutics

Phase 1

2 10

Ic9-CAR.B7-H3 T Cells

UUNC Lineberger Comprehensive Cancer Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2039

Phase 1Active, not recruiting

T Cells

NCT03602157

Clinical

Trials by Indication[1]

T Cells1 trial

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03602157·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALTCAR.CD30 cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALTCAR.CD30 cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALTCAR.CD30 cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUNC Lineberger Comprehensive Cancer Center

ALTCAR.CD30 cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2039

Trials by Indication[1]

T Cells1 trial

References

Drug Info

Quick Facts

Related News